安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- PADCEV® (enfortumab vedotin-ejfv) Mechanism of Action
PADCEV® MECHANISM OF ACTION (MOA) PADCEV is an antibody-drug conjugate (ADC) directed against Nectin‑4 1 Nectin-4 is an adhesion protein located on the surface of cells Nonclinical data suggest that the anticancer activity of PADCEV (enfortumab vedotin-ejfv) is a result of the following:
- Enfortumab vedotin - Wikipedia
Enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate [6] used for the treatment of urothelial cancer [4][7] It is a nectin-4 -directed antibody and microtubule inhibitor conjugate [4][7] Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker
- LABEL - Food and Drug Administration
PADCEV is a Nectin-4-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant
- Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
28 Astellas and Seattle Genetics receive FDA breakthrough therapy designation for PADCEV (enfortumab vedotin-ejfv) in combination with pembrolizumab in first-line advanced bladder cancer
- Enfortumab vedotin: Uses, Interactions, Mechanism of Action | DrugBank . . .
Enfortumab vedotin is an antibody-drug conjugate comprised of a fully human monoclonal antibody and microtubule-disrupting chemotherapeutic agent used in the treatment of advanced or metastatic urothelial cancer
- DRUG NAME: Enfortumab vedotin - BC Cancer
MECHANISM OF ACTION: Enfortumab vedotin is a fully human IgG1 kappa antibody-drug conjugate directed against Nectin-4, an adhesion protein located on the surface of cells The monoclonal antibody component (AGS-22C3) is conjugated to the small molecule microtubule-disrupting agent (monomethyl auristatin E or MMAE) via a protease-cleavable linker Internalization of the antibody-drug conjugate
- Enfortumab Vedotin - LiverTox - NCBI Bookshelf
Enfortumab vedotin is a human monoclonal antibody conjugate that is used in the therapy of refractory, locally advanced or metastatic urothelial cancer Enfortumab vedotin has been linked to transient, mild-to-moderate serum enzyme elevations during therapy but has not been implicated in instances of clinically apparent liver injury with jaundice
- PADCEV® (enfortumab vedotin-ejfv) | Official Patient Site
Learn more about PADCEV® Find information on efficacy, dosing, resources, and more Please see full Prescribing Information, including Serious Side Effects
|
|
|